Todd Aguilera, M.D. Ph.D.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Intellectual Property Other
    Ineligible company:
    UC San Diego
    Topic:
    Royalties
    Date added:
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Intellectual Property Other
    Ineligible company:
    Stanford University
    Topic:
    Royalties
    Date added:
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    iTeos
    Topic:
    Sponsored Research
    Date added:
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Avelas Biosciences
    Topic:
    founder shares
    Date added:
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Galera Therapeutics
    Topic:
    Sponsored Research Pancreatic cancer trial
    Date added:
    Date updated:
    03/14/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Apexigen Inc
    Topic:
    Research funding for investigator initiated trial
    Date added:
    Date updated:
    03/14/2024
Return to 156 Renal Cell Carcinoma Multimodality Conference: (080122)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.